ProQR (PRQR) – Company Press Releases
-
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
-
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
-
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
-
ProQR Announces Year End 2023 Operating and Financial Results
-
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
-
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
-
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
-
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
-
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
-
ProQR Announces Third Quarter 2023 Operating and Financial Results
-
ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
-
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
-
ProQR Therapeutics Provides Update on Ophthalmic Assets
-
ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
-
ProQR Announces Second Quarter 2023 Operating and Financial Results
-
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
-
ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit
-
ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit
-
ProQR Announces First Quarter 2023 Operating and Financial Results
-
ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023
-
ProQR Announces Upcoming Investor Conferences in April and May
-
ProQR Announces Upcoming Investor Conferences in April and May
-
ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023
-
ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023
-
ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
-
ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
-
ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing
-
ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing
-
ProQR to Present at Upcoming Scientific and Industry Conferences
-
ProQR to Present at Upcoming Scientific and Industry Conferences
-
ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023
-
ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023
-
ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
-
ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
-
Lilly and ProQR to Expand RNA Editing Collaboration
-
Lilly and ProQR to Expand RNA Editing Collaboration
-
Lilly and ProQR to Expand RNA Editing Collaboration
-
ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022
-
ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022
-
ProQR Announces Third Quarter 2022 Operating and Financial Results
-
ProQR Announces Third Quarter 2022 Operating and Financial Results
-
ProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Healthcare Conference
-
ProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Healthcare Conference
-
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs
-
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs
-
ProQR Announces Second Quarter 2022 Operating and Financial Results
-
ProQR Announces Second Quarter 2022 Operating and Financial Results
-
ProQR to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium
-
ProQR to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium
-
ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates
Back to PRQR Stock Lookup
